ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21 USD | +11.29% |
|
+5.69% | -1.96% |
| 16/04 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| 11/04 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
| Sales 2024 * | 16.39M 1.37B | Sales 2025 * | 25.59M 2.13B | Capitalization | 574M 47.83B |
|---|---|---|---|---|---|
| Net income 2024 * | -178M -14.84B | Net income 2025 * | -196M -16.34B | EV / Sales 2024 * | 17.7 x |
| Net cash position 2024 * | 283M 23.6B | Net cash position 2025 * | 316M 26.33B | EV / Sales 2025 * | 10.1 x |
| P/E ratio 2024 * |
-3.32
x | P/E ratio 2025 * |
-3.58
x | Employees | 117 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on AnaptysBio, Inc.
More recommendations
More press releases
| 1 day | +11.29% | ||
| 1 week | +5.69% | ||
| Current month | -6.75% | ||
| 1 month | -2.78% | ||
| 3 months | -11.05% | ||
| 6 months | +23.67% | ||
| Current year | -1.96% |
1 week
18.49
21.61
1 month
18.4925.62
Current year
18.4927.50
1 year
13.3627.50
3 years
13.3637.89
5 years
10.0079.09
10 years
10.00134.00
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 26/21/26 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 15/20/15 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 31/20/31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 30/15/30 |
Dennis Fenton
BRD | Director/Board Member | 72 | 05/18/05 |
Magda Marquet
BRD | Director/Board Member | 65 | 18/21/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.02% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 21 | +11.29% | 649,412 |
| 25/24/25 | 18.87 | -2.08% | 401,012 |
| 24/24/24 | 19.27 | +0.47% | 385,671 |
| 23/24/23 | 19.18 | -2.44% | 387,321 |
| 22/24/22 | 19.66 | -1.06% | 139,714 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
21
USD
Average target price
43.5
USD
Spread / Average Target
+107.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.96% | 574M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ANAB Stock
